Cancer is a genetic disease caused by mutations, chromosomal abnormalities and chromatin changes that alter gene expression and protein function. This simple statement is the foundation of the Genome Maintenance Research Program (GM). GM is a cohesive network of basic science researchers whose collective mission is to understand processes affecting the integrity, expression and duplication of genetic material. This mission consists not only of explaining the etiology of cancer, but also understanding how existing therapeutics work, and identifying opportunities for new therapeutic development. The Program promotes the highest level of scientific discovery by fostering interactions among members, educating members on opportunities for collaborative research with other programs, and serving as a genome-centric resource for the entire Vanderbilt-Ingram Cancer Center (VICC). Research interests of GM members include carcinogen metabolism, DNA metabolism, DNA damage responses, chromatin and gene expression, epigenetics, and the cell division cycle. There are 26 program members of GM from 11 departments and two schools, with $5.4M in NCI funding and $7M in other peer-reviewed cancer-related funding. Out of 399 publications, 15% are intra-programmatic and 21% are inter-programmatic. Members also have 160 collaborative publications with investigators at other institutions.

Public Health Relevance

The Vanderbilt-Ingram Cancer Center (VICC) is a matrix center that integrates all of Vanderbilt University's cancer-related expertise and resources in order to deliver its mission of alleviating cancer death and suffering through pioneering research; innovative patient-centered care; and evidence-based prevention, education and community initiatives. This is accomplished through translation of exceptional cancer research into interventions for the prevention and treatment of cancer. The Cancer Center Support Grant provides infrastructure to facilitate multidisciplinary basic, clinical and population-based research, to advance our discoveries to cancer patients and the community and to educate and train the next generation of cancer investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-23
Application #
9553494
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-09-17
Project End
2020-08-31
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
23
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Covington, Brett C; Spraggins, Jeffrey M; Ynigez-Gutierrez, Audrey E et al. (2018) Response of Hypogean Actinobacterial Genera Secondary Metabolism to Chemical and Biological Stimuli. Appl Environ Microbiol :
Hong, Jun; Maacha, Selma; Belkhiri, Abbes (2018) Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma. Mol Oncol 12:2191-2208
Dahlman, Kimberly Brown; Weinger, Matthew B; Lomis, Kimberly D et al. (2018) Integrating Foundational Sciences in a Clinical Context in the Post-Clerkship Curriculum. Med Sci Educ 28:145-154
Ramsey, Haley E; Fischer, Melissa A; Lee, Taekyu et al. (2018) A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov 8:1566-1581
Wu, Jie; Cai, Hui; Xiang, Yong-Bing et al. (2018) Intra-individual variation of miRNA expression levels in human plasma samples. Biomarkers 23:339-346
Bolus, W Reid; Peterson, Kristin R; Hubler, Merla J et al. (2018) Elevating adipose eosinophils in obese mice to physiologically normal levels does not rescue metabolic impairments. Mol Metab 8:86-95
Yang, Jinming; Kumar, Amrendra; Vilgelm, Anna E et al. (2018) Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Cancer Immunol Res 6:1186-1198
Alvarado, Gabriela; Ettayebi, Khalil; Atmar, Robert L et al. (2018) Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses. Gastroenterology 155:1898-1907
Cardin, Dana B; Goff, Laura W; Chan, Emily et al. (2018) Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs 36:442-450
Garcia, A Denise R; Han, Young-Goo; Triplett, Jason W et al. (2018) The Elegance of Sonic Hedgehog: Emerging Novel Functions for a Classic Morphogen. J Neurosci 38:9338-9345

Showing the most recent 10 out of 2462 publications